Evaxion Biotech A/S (NASDAQ:EVAX) Given “Buy” Rating at HC Wainwright

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $14.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 434.35% from the stock’s current price.

Evaxion Biotech A/S Stock Down 5.1 %

Shares of EVAX opened at $2.62 on Friday. The stock has a 50 day moving average price of $2.97 and a 200 day moving average price of $3.21. Evaxion Biotech A/S has a one year low of $2.26 and a one year high of $13.61. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 2.80. The stock has a market capitalization of $14.62 million, a price-to-earnings ratio of -1.11 and a beta of -0.26.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The business had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $0.19 million. Equities research analysts forecast that Evaxion Biotech A/S will post -0.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Armistice Capital LLC increased its stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 392,000 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Armistice Capital LLC owned about 7.24% of Evaxion Biotech A/S worth $1,137,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.